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Waldenstro¨m’s macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal
gammopathy and bonemarrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics ofWM in Asia including
Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel
agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with
novel agent and conventional chemotherapy in Republic of Korea. Data from all (𝑛 = 71) patients with newly diagnosed WM
at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median
age of patients was 66 years (range: 37–92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined
chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%,
𝑃 = 0.006).The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73–111.07). Use of novel agents produced higher
ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are
needed to confirm the efficacy of novel agents in patients with WM.
1. Introduction
The consensus group at the Second International Work-
shop on Waldenstro¨m’s macroglobulinemia (WM) in 2002
redefined WM as a distinct clinicopathologic entity charac-
terized by bone marrow infiltration by lymphoplasmacytic
lymphoma (LPL) and immunoglobulinM (IgM)monoclonal
gammopathy [1]. Diagnostic criteria for WM are IgM mon-
oclonal gammopathy of any concentration, bone marrow
infiltration by small lymphocytes showing plasmacytoid or
plasma cell differentiation, intertrabecular pattern of bone
marrow infiltration, and surface IgM+, CD5±, CD10−, CD19+,
CD20+, CD22+, CD23−, CD25+, CD27+, FMC7+, CD103−,
and CD138− immunophenotype [2].
WM is a very rare lymphoid malignancy, with an overall
incidence estimated at 0.35 forWMand0.63 for LPL/WMper
100,000 person-years during 2001–2003, representing 1.2% or
2.1% of all non-Hodgkin’s lymphomas in the United States
Surveillance Epidemiology and End Results (SEER) cancer
registries, respectively [3]. Between 1996 and 2003, the crude
incidence of LPL/WM was 0.078 per 100,000 person-years
in Japan (0.112 for men and 0.048 for women) and 0.032 per
100,000 person-years in Taiwan (0.042 for men and 0.021 for
women) [4]. A previous nationwide survey of the incidence
of lymphoma based on the REAL classification reported the
incidence of LPL in Korea as 0.8%, with the exact incidence
rate of WM/LPL not recognized [5]. The incidence rate of
WM is lower in the Republic of Korea than those in the USA,
which was documented to be about 0.3 per million person-
years according to data of the National Cancer Information
Center in the Republic of Korea.
The most common clinical manifestations are hep-
atomegaly (20%), splenomegaly (15%), and lymphadenopa-
thy (15%) [6]. The most common presenting symptom is
fatigue related to normochromic or normocytic anemia. The
median hemoglobin value at diagnosis is 10 g/dL [7]. Patients
with a disease-related hemoglobin level <10 g/dL, platelet
count <100 × 109/L, bulky adenopathy or organomegaly,
symptomatic hyperviscosity,moderate to severe or advancing
peripheral neuropathy on the basis of disease, symptomatic
amyloidosis, cryoglobulinemia, or cold-agglutinin disease
should be considered for therapy but asymptomatic patients
should be observed [8]. Recently, the superior efficacy of
chemotherapy combined with novel agent including ritux-
imab, bendamustine, bortezomib, lenalidomide, and thalido-
mide than that of conventional chemotherapy has been estab-
lished. However, little is known about the clinical features,
epidemiology, and cytogenetics of WM in Asia including the
Republic of Korea. Novel agent combined chemotherapy for
patients with WM has been restricted in the Republic of
Korea because of very low incidence and insurance coverage
limitation.
Treatment outcomes in the Republic of Korea patients
with WM treated by novel agent combined chemotherapy
are unclear. This study is aimed at investigating the clinical
features and assess the treatment outcomes of novel agent
combined chemotherapy and conventional chemotherapy.
2. Materials and Methods
2.1. Patients. Data from 71 patients newly diagnosed with
WM who received chemotherapy at 17 university hospi-
tals in the Republic of Korea between January 2005 and
December 2012 were collected retrospectively. All cases
fulfilled the diagnostic criteria [1] and were confirmed as
WM by hematopathologists and hematologists. The pre-
treatment evaluation included a physical examination with
performance status evaluation, complete blood cell count
with differential count, blood chemistry including lactase
dehydrogenase (LDH), protein electrophoresis (PEP), IgM,
free light chain kappa and lambda, bonemarrowbiopsy, chro-
mosomal study, fluorescence in situ hybridization (FISH),
and computed tomography (CT) of the chest, abdomen, and
pelvis.
2.2. Treatment. All patients were treated with conventional
chemotherapy or chemotherapy along with novel agent
(rituximab, bortezomib, thalidomide, and bendamustine).
Bendamustine is old chemotherapeutic agent but recently the
roles of this drug were rediscovered by its efficacy and toxici-
ties in indolent lymphoma including WM [9, 10]. Rituximab
combined chemotherapy included rituximab, cyclophos-
phamide, vincristine, and prednisolone (R-CVP) and ritux-
imab, cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone (R-CHOP). Bortezomib combined chemotherapy
included bortezomib plus dexamethasone (VD). Thalido-
mide combined chemotherapy included thalidomide plus
dexamethasone (TD) and thalidomide plus cyclophos-
phamide and dexamethasone (TCD). Bendamustine was
used along with prednisolone. Conventional chemother-
apy included chlorambucil, CVP, CHOP, melphalan plus
prednisolone (MP), cyclophosphamide plus prednisolone
(CP), fludarabine plus cyclophosphamide (FC), and flu-
darabine plus cyclophosphamide and mitoxantrone (FCM).
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All patients were treated with one or more chemother-
apeutic regimens. Patients who displayed progression or
intolerance against previous chemotherapy were changed
from chemotherapy to a salvage regimen. Introduction of
novel agents was applied to four patients as first-line, three
as second-line, five at third-line, and two at fourth-line
chemotherapy.
2.3. Analysis. Overall response rates (ORR) of patients
treated with conventional and novel therapy were esti-
mated as the best response at first-line and applied peri-
ods. ORR were estimated by clinical para-meters in all
patients including age, sex, hemoglobin levels, platelet
counts, absolute lymphocyte counts (ALC), C-reactive pro-
tein (CRP), LDH, serum 𝛽2-microglobulin, serum albumin,
hepatosplenomegaly, Eastern Cooperative Oncology Group
(ECOG) performance status, presence of B symptoms, and
hyperviscosity syndrome. Those clinical parameters and
international staging system (ISS), International Prognos-
tic Scoring System for Waldenstrom’s Macroglobulinemia
(ISSWM), and treatment modalities were estimated to find
prognostic markers for survival. The treatment response was
assessed according to the Sixth International Workshop on
WM [11].
2.4. Statistical Analyses. We investigated independent prog-
nostic factors associated with survival in above clinical and
laboratory parameters.The definition of overall survival (OS)
was calculated from the date of diagnosis to the date of
death from disease-related cause or final follow-up date.
Progression-free survival (PFS) was from the date of start-
ing treatment (conventional chemotherapy or novel agent
combined chemotherapy) to the date of disease progression,
relapse, or death from disease-related cause. Associations
between the clinical parameters and ORR were analyzed
using the chi-square test. A multiple logistic regression anal-
ysis was used for multivariate analysis of independent prog-
nostic factors for ORR. Survival probabilities were calculated
according to the Kaplan-Meier method and compared using
the log-rank test. The Cox proportional hazards regression
model was used for multivariate analysis of independent
prognostic factors for survival. Information about the base-
line medical status and treatment modalities was collected
from the medical records. Approval for these studies was
obtained from the Institutional Review Board.
3. Results
3.1. Clinical and Laboratory Characteristics. The median age
of the 71 patients was 66 years (range: 37–92 years) and the
male to female ratio was 5 : 1 (Table 1). 25.4% and 38.0% of
patients had clinical or radiological evidence of splenomegaly
and of lymphadenopathy, respectively. 11.3% of patients had B
symptoms before the initiation of treatment. Hyperviscosity
and involvement of other organs were shown in 11.3% and
40.8% of patients, respectively. The median serum mono-
clonal protein level was 3.640 g/dL (range: 0.0183–10.795).
The cytogenetic abnormalities identified included deletion of
the long arm of chromosome 6 in two cases and absence of
Table 1: Clinical and laboratory characteristics.
Characteristic 𝑁 (%) or median (range)
Patients 71
Age, years, median (range) 66 (37–92)
Gender
Male 59 (83.1)
Female 12 (16.9)
Hemoglobin, g/dL, median (range) 9.6 (3.80–17.10)
Platelet count, ×109/L, median (range) 213 (23–575)
ALC, ×109/L, median (range) 1.70 (0.10–12.30)
CRP, mg/dL, median (range) 2.44 (0.05–23.80)
Serum 𝛽2-microglobulin, mg/L,
median (range) 4.20 (1.34–30.00)
Serum albumin, g/dL, median (range) 3.2 (1.50–4.60)
LDH, IU/L, median (range) 261.0 (74.0–968.0)
BM lymphocyte, %, median (range) 14 (5–100)
Cytogenetic abnormalities, present (%) 8 (11.3%)
Serum monoclonal protein, mg/dL,
median (range) 3640.0 (18.30–10795.0)
B symptom, present (%) 8 (11.3)
ECOG (%) ≥2 23 (32.4)
Hyperviscosity, present (%) 8 (11.3)
Lymphadenopathy, yes (%) 27 (38.0)
Extranodal involvement, yes (%) 29 (40.8)
Splenomegaly, yes (%) 18 (25.4)
Hepatomegaly, yes (%) 7 (9.9)
ISS (%)
I 13 (18.3)
II 26 (36.6)
III 26 (36.6)
Unknown 6 (8.5)
Treatment regimen
Novel agent combined
chemotherapy 14 (19.7)
Conventional chemotherapy 57 (80.3)
Treatment
Novel group
R-combined CTx; R-CVP, R-CHOP 6 (8.5)
VD 5 (7.0)
TD 2 (2.8)
Bendamustine plus prednisolone 1 (1.4)
Conventional group
Chlorambucil 25 (35.2)
CVP or CHOP 14 (19.7)
MP or CP 15 (21.1)
FC or FCM 3 (4.2)
ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate
dehydrogenase; BM: bone marrow; ECOG: Eastern Cooperative Oncology
Group performance status; ISS: international staging system; R-combined
CTx: rituximab combined chemotherapy; R-CVP: rituximab, cyclophos-
phamide, vincristine, and prednisolone; R-CHOP: rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisolone; VD: bortezomib plus
dexamethasone; TD: thalidomide plus dexamethasone; MP: melphalan plus
prednisolone; CP: cyclophosphamide plus prednisolone; FC: fludarabine
plus cyclophosphamide; FCM: fludarabine plus cyclophosphamide and
mitoxantrone.
trisomy 4. Other cytogenetic abnormalities were identified in
11.3% of cases. Other clinical or laboratory characteristics are
summarized in Table 1.
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3.2. Treatment and Outcomes. The 71 patients were treated
with novel agent combined chemotherapy or conventional
chemotherapy. 25 patients were treated with chlorambucil
with or without prednisone, 14 were treated with CVP
or CHOP regimen, 15 were treated with the MP or CP
regimen, and three were treated with FC or FCM as first-
line therapy. Other patients were treated with novel agent
combined chemotherapy. Six patients were treated with R-
CVP, R-CHOP, five with VD, two with thalidomide plus dex-
amethasone, and one with bendamustine plus prednisolone
(Table 1). Overall, an objective response (complete or partial
response) and more than minimal response (MR) rates were
documented in 53.5% and 69.0% of patients, respectively.The
median follow-up was 22.97 months. The 5-year PFS and OS
rates were 50.5% and 62.6% (95% confidence interval (95%
CI): 48.32–81.41 and 34.73–111.07), respectively.
3.3. Analysis of Prognostic Factors for Response and Survival.
Multiple parameters were analyzed for their possible prog-
nostic impact on ORR and OS. Univariate analysis showed
that the following factors were associated with higher ORR
(Table 2): higher ALC (<1.0× 109/L versus≥1.0× 109/L; 20.0%
versus 64.6%, 𝑃 = 0.069), good ECOG performance status
(<2 versus ≥2; 67.4 versus 43.5, 𝑃 = 0.057), and novel agent
combined chemotherapy versus conventional chemotherapy
(92.9% versus 52.6%, 𝑃 = 0.006). The following factors
were associated with superior 5-year OS (Table 2): younger
age (<65 years versus ≥65 years; 82.2% versus 36.8%, 𝑃 =
0.024), good ECOG performance status (<2 versus ≥2; 72.6%
versus 26.9%, 𝑃 = 0.004), higher serum albumin levels
(<3.5 g/dL versus ≥3.5 g/dL; 44.8% versus 84.1%, 𝑃 = 0.010),
lower risk international staging system (ISS I, II, and III;
85.7%, 84.8%, and 36.8%, resp.; 𝑃 = 0.004), and novel agent
combined chemotherapy versus conventional chemotherapy
(100% versus 53.0%, 𝑃 = 0.067). In the multivariate analysis,
novel agent combined chemotherapy was an independent
prognostic value for ORR (𝑃 = 0.046) and lower ISS was an
independent prognostic value for OS (𝑃 = 0.008) (Table 3).
4. Discussion
The clinical manifestations and laboratory abnormalities
associated with WM are related to direct tumor infiltration
and to the amount and specific properties ofmonoclonal IgM.
The most common symptoms are weakness and fatigue, usu-
ally secondary to anemia. Symptoms of weight loss, excessive
sweating, and low-grade fever affect a quarter of patients.
Hepatomegaly, splenomegaly, and lymphadenopathy each
occur in 15%–30% of patients. Similarly, previous Korean
studies reported the most common symptoms as anemia and
thrombocytopenia, with other frequently expressed symp-
toms being (20–40%), hepatosplenomegaly (25–35%), and
lymphadenopathy (25–40%) [12–14]. In this study, anemia
was the most frequent symptom and thrombocytopenia
was secondary frequent symptom with lymphadenopathy,
hepatomegaly, and splenomegaly being expressed in 10–
40% of the cases. However, hyperviscosity syndrome was
documented only in eight cases, which was a relatively low
incidence compared towestern results [6].Themost common
cytogenetic abnormality was deletion of the long arm of
chromosome 6 (6q deletion) and trisomy 4 [15, 16]. However,
there was only one report about cytogenetics of Korean WM
patients, which documented a low rate of 6q deletion (10%)
and no trisomy 4 [13]. Similar to a previous Korean study,
this study documented a low rate of 6q deletion and other
cytogenetic abnormalities.
In this study, novel agent combined chemotherapy was
the only independent predictive factor for response rates,
although higher ALC count and good performance status
were also associated with higher ORR in univariate analysis.
Many studies have been shown to improve response and
survival rates in patients with WM. Gertz et al. presented
meaningful results about efficacy of rituximab in patients
with WM [17]. The efficacy of rituximab in WM has been
amply described. Rituximab combined chemotherapy includ-
ing R-CHOP, R-CVP, R-CP, R-F (fludarabine), R-cladribine,
and R-CD (cyclophosphamide and dexamethasone) pro-
duces superior response rates to conventional chemotherapy
[18–23]. Rituximab combined with thalidomide reportedly
produced a 72% response rate, and rituximab combined
with lenalidomide produced a 50% response rate [24, 25].
Bortezomib has high levels of activity in the management
of relapsed WM with response rates ranging from 81%
to 96% [26, 27]. In a prospective randomized study of
bendamustine plus rituximab compared with R-CHOP in
patients with WM, of whom 22 received bendamustine and
rituximab and 19 received R-CHOP, the response rate was
95% in both groups, but median progression-free survival
was significantly prolonged with bendamustine. The median
progression-free survival for R-CHOPwas 36months in con-
trast to not being reached with bendamustine and rituximab
(𝑃 < 0.0001) [28].
In our study, only lower risk ISS showed superior survival
to those of higher risk ISS although younger age, good
performance status, higher serum albumin levels, and novel
agent combined chemotherapy were associated with longer
OS in univariate analysis. Patients treated with novel agent
combined chemotherapy especially did not show superior
survival rates to conventional chemotherapy in spite of
higher ORR in patients receiving novel agents. These results
might be associated with small sample size, short follow-
up duration, and the clinical features of WM (which seems
to be indolent lymphoma). Prior studies have documented
several prognostic factors for survival [29–33]. Age, anemia,
leukopenia, thrombocytopenia, serum albumin levels, and
𝛽2-microglobulin values were linked to survival. However,
these prognostic factors were not meaningful in this study.
Very low incidence rates ofWMand restriction of using novel
agents because of the limitation of medical reimbursement
in Korea might be reasons for the insufficient comparison
between novel agent combined chemotherapy and conven-
tional chemotherapy in this study.
5. Conclusions
Clinical features of Korean WM are similar to western
WM, except for the low incidence of hyperviscosity syn-
drome. Response rates after chemotherapy were improved by
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Table 2: Clinical and laboratory values associated with survival on univariate analysis.
Characteristic ORR ≥ PR (%) 𝑃 5-year PFS (%) 𝑃 5-year OS (%) 𝑃
Age, years
<65 66.7 0.327 64.8 0.708 82.2 0.024
≥65 55.3 37.0 36.8
Gender
Male 64.4 0.197 46.8 0.530 65.9 0.130
Female 41.7 77.9 45.0
BM lymphocyte, %
<50 63.0 0.461 61.8 0.478 40.6 0.610
≥50 52.9 26.2 52.5
Cytogenetic abnormalities
Presence 75.0 0.466 64.3 0.599 50.0 0.444
Absence 58.7 50.9 42.4
Hemoglobin, g/dL
<11.5 61.3 0.732 54.3 0.140 60.2 0.700
≥11.5 55.6 0.0 87.5
Platelet count, ×109/L
<100 69.2 0.479 0.0 0.049 61.9 0.124
≥100 58.6 60.6 63.0
ALC, ×109/L
<1.0 20.0 0.069 33.3 0.611 40.0 0.224
≥1.0 64.6 54.3 64.6
CRP, mg/dL
<5 58.0 0.817 46.4 0.937 65.5 0.096
≥5 61.5 51.3 48.6
Serum 𝛽2-microglobulin, mg/L
<3 66.7 0.862 48.9 0.130 50.0 0.143
≥3 64.0 50.6 58.4
Serum albumin, g/dL
<3.5 58.5 0.683 43.1 0.712 44.8 0.010
≥3.5 63.3 64.4 84.1
LDH, IU/L
<450 59.7 0.688 50.1 0.849 61.8 0.403
≥450 66.7 65.6 72.9
B symptom
Presence 87.5 0.132 83.3 0.666 60.0 0.385
Absence 56.5 48.8 62.8
ECOG, (%)
0-1 67.4 0.057 68.7 0.012 72.6 0.004
≥2 43.5 18.1 26.9
Hyperviscosity syndrome
Presence 25.0 0.055 58.3 0.980 0.0 0.918
Absence 63.8 49.7 66.2
Splenomegaly
Presence 61.1 0.838 77.4 0.342 0.0 0.300
Absence 58.3 49.5 52.7
Hepatomegaly
Presence 57.1 0.884 40.0 0.246 28.6 0.913
Absence 60.0 42.5 45.1
ISSWM (%)
Low 57.1
0.567
66.7
0.912
50.0
0.380Intermediate 58.8 58.7 58.0
High 75.0 0.0 58.4
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Table 2: Continued.
Characteristic ORR ≥ PR (%) 𝑃 5-year PFS (%) 𝑃 5-year OS (%) 𝑃
ISS (%)
I 61.5
0.522
48.7
0.714
85.7
0.004II 69.2 41.9 84.8
III 53.8 64.7 36.8
Treatment regimen
Novel agent combined chemotherapy 92.9 0.006 79.1 0.418 100.0 0.067Conventional chemotherapy 52.6 46.3 53.0
ORR: overall response rates; PR: partial response rates; 5-year PFS: 5-year progression-free survival rates; 5-year OS: 5-year overall survival rates; BM: bone
marrow; ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase; ECOG: Eastern Cooperative Oncology Group performance
status; ISSWM: International Prognostic Scoring System for Waldenstrom’s Macroglobulinemia; ISS: international staging system.
Table 3: Multivariate analysis for response and survival.
Value ORR OS
RR 95% CI 𝑃 value RR 95% CI 𝑃 value
Age, years
<65
≥65 1.021 0.350–2.980 0.970
ALC, ×109/L
<1.0
≥1.0 0.362 0.060–2.193 0.369
ECOG (%)
0-1
≥2 2.006 0.711–5.660 0.188 0.421 0.147–1.208 0.108
Serum albumin, g/dL
<3.5
≥3.5 1.123 0.264–4.772 0.875
ISS (%)
I
II 0.439 0.078–2.486 0.352
III 0.209 0.066–0.665 0.008
Treatment regimen
Novel agent combined chemotherapy
Conventional chemotherapy 5.048 1.032–24.702 0.046 0.368 0.075–1.803 0.217
ORR: overall response rates; OS: overall survival rates; RR: relative risk; 95% CI: 95% confidence interval; ALC: absolute lymphocyte count; ECOG: Eastern
Cooperative Oncology Group performance status; ISS: international staging system.
introduction of novel agents such as rituximab, bortezomib,
thalidomide, and bendamustine, although survival benefit
was not shown. Independent prognostic factor for survival
was high risk ISS inKoreanWM.However, further studywith
more patients is needed to determine the efficacy of novel
agent combined chemotherapy and to definitively identify the
prognostic factors.
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